Article Text

other Versions

PDF
The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis
  1. H W van Steenbergen1,
  2. S Ajeganova2,
  3. K Forslind3,4,
  4. B Svensson3,
  5. A H M van der Helm-van Mil1
  1. 1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2Rheumatology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
  3. 3Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
  4. 4Section of Rheumatology, Department of Medicine, Helsingborgs Lasarett, Helsingborg, Sweden
  1. Correspondence to Dr Sofia Ajeganova, Rheumatology Unit R92, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm 14186, Sweden; sofia.ajeganova{at}ki.se

Statistics from Altmetric.com

With interest we read the article by Hecht et al1 who studied the associations of anticitrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) with bone erosions in rheumatoid arthritis (RA). The background of this study was that ACPAs directed against citrullinated vimentin induce differentiation of osteoclasts, indicating that ACPA has a direct effect on bone resorption.2 No biological data are available on whether RF also affects bone cells and, given the overlap between ACPA-positivity and RF-positivity, the authors wanted to distinguish the association between RF and bone erosions from the association between ACPA and bone erosions. In a cross-sectional study, high-resolution peripheral quantitative CT (HR-pQCT) images of metacarpophalangeal (MCP) 2–4 joints of 238 patients with RA were made and groups of patients with different combinations of autoantibodies were compared. The authors observed mainly differences in erosive burden in patients with both antibodies compared with those without antibodies. In a subgroup analysis, they also reported a higher erosive burden in ACPA+/RF+ patients compared with ACPA+/RF− patients. Based on their findings the authors suggested that RF may act as an enhancer of bone loss in ACPA-positive patients.

HR-pQCT is an interesting tool that admits …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles